Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
|Articles|August 17, 2009
- ONCOLOGY Vol 23 No 9
- Volume 23
- Issue 9
New Drug Application Filed for Vandetanib in Second-Line NSCLC
AstraZeneca announced the company has submitted a New Drug Application to the FDA for an investigational drug, vandetanib ( Zactima) 100 mg, for use in combination with chemotherapy for the treatment of advanced non–small-cell lung cancer in patients previously treated with one prior anticancer therapy.
Advertisement
Articles in this issue
about 17 years ago
Testicular Granulosa Cell Tumors: Rare Tumors Need to Be Studied Tooabout 17 years ago
Metabolic Therapiesabout 17 years ago
Bevacizumab Approved for Metastatic Renal Cell Carcinomaabout 17 years ago
Project Zero Delay Accelerates Drug’s Path to Clinical Trialabout 17 years ago
New Directions in the Systemic Treatment of Metastatic Thyroid Cancerabout 17 years ago
Radioiodine-Resistant Differentiated Thyroid Cancer: Hope for the Futureabout 17 years ago
Therapeutic Options Following Orchiectomy for Stage I SeminomaAdvertisement
Related to this article
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5